We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Today, Plantsulin blends this century-old discovery with modern scientific validation to offer a fast, convenient "whole-body ...
News Medical on MSN6d
Unlocking the potential of receptor-based approaches in diabetes treatmentAnnouncing a new article publication for BIO Integration journal. Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...
Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...
This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback